Overall rank by patents
#49,955
Across all tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, active 2016–2021. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
Reckitt holds 5 US patents across 5 technology areas, rank #49,955 of 50,000 tracked assignees.
Reckitt Benckiser Healthcare (uk) Limited has been granted 5 US utility patents between 2016 and 2021, placing Reckitt Benckiser Healthcare (uk) Limited at rank #49,955 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Reckitt Benckiser Healthcare (uk) Limited is one of the more focused assignees in the PatentsView dataset. By volume, Reckitt sits between RE Factor Tactical, Llc (5 patents, rank #49,951) and REED Manufacturing Company (5 patents, rank #49,959) - the closest US assignees by grant volume. The composite Innovation Score of 23.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 4 in the 2015–2019 window, a -75% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Reckitt Benckiser Healthcare (uk) Limited's 16.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Reckitt Benckiser Healthcare (uk) Limited against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
RE FACTOR TACTICAL, LLC
5 patents
RE MAGO LTD
5 patents
REA Innovations, Inc.
5 patents
REALYAGU ZONE CO., LTD.
5 patents
RECOVERED ENERGY, INC.
5 patents
RECYCLEBANK LLC
5 patents
RED BOX RECORDERS LIMITED
5 patents
REED MANUFACTURING COMPANY
5 patents
RECKITT BENCKISER HEALTHCARE (UK) LIMITED
5 patents
What this shows Reckitt holds 5 patents at rank #49,955, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #49,955 in granted patent volume.
Other assignees with the most granted patents in Reckitt's primary technology class.
Reckitt's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
24 Top 87% higher than 13% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 20.0% |
| 2017 | 1 | 20.0% |
| 2019 | 2 | 40.0% |
| 2021 | 1 | 20.0% |
Top 5 of 5 technology areas
Overall rank by patents
#49,955
Across all tracked assignees
23.8 out of 100
How to use this portfolio
Reckitt's 5 grants land it in the top 87% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.